These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The management of localized prostate cancer. Clarke NW Br J Hosp Med; 1996 Mar 6-19; 55(5):232-3. PubMed ID: 8777510 [No Abstract] [Full Text] [Related]
3. Natural history and staging of prostate cancer. Whitmore WF Urol Clin North Am; 1984 May; 11(2):205-20. PubMed ID: 6375067 [TBL] [Abstract][Full Text] [Related]
4. Adenocarcinoma of the prostate. Von Eschenbach AC; Johnson DE Compr Ther; 1978 Aug; 4(8):18-26. PubMed ID: 688739 [No Abstract] [Full Text] [Related]
5. More about prostate cancer--expectant management versus treatment. Anscher MS N C Med J; 1999; 60(6):313-4. PubMed ID: 10581934 [No Abstract] [Full Text] [Related]
11. Best practice statement on cryosurgery for the treatment of localized prostate cancer. Babaian RJ; Donnelly B; Bahn D; Baust JG; Dineen M; Ellis D; Katz A; Pisters L; Rukstalis D; Shinohara K; Thrasher JB J Urol; 2008 Nov; 180(5):1993-2004. PubMed ID: 18817934 [No Abstract] [Full Text] [Related]
12. Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate. Anscher MS; Clough R; Robertson CN; Prosnitz LR; Dahm P; Walther P; Donatucci CF; Albala DM; Febbo P; George DJ; Sun L; Moul JW Prostate Cancer Prostatic Dis; 2006; 9(3):254-60. PubMed ID: 16880828 [TBL] [Abstract][Full Text] [Related]
13. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals. Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106 [TBL] [Abstract][Full Text] [Related]
14. Long-term outcome for lymph node-positive prostate cancer. Swanson GP; Riggs MW; Herman M Prostate Cancer Prostatic Dis; 2008; 11(2):198-202. PubMed ID: 17519924 [TBL] [Abstract][Full Text] [Related]
15. Natural history of prostatic cancer. Hanash KA Prog Clin Biol Res; 1987; 243B():289-320. PubMed ID: 3659027 [No Abstract] [Full Text] [Related]
16. Difficult diagnostic and therapeutic cases: CASE 3. presentation of prostate cancer with cervical adenopathy. Gaur S; Aish LS; Oo TH J Clin Oncol; 2004 Mar; 22(5):957-8. PubMed ID: 14990654 [No Abstract] [Full Text] [Related]
17. [Prognosis of prostate cancer with elevated prostatic acid phosphatase]. Saito T; Kitamura Y; Komatsubara S Hinyokika Kiyo; 2006 Mar; 52(3):177-80. PubMed ID: 16617869 [TBL] [Abstract][Full Text] [Related]
18. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma. Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760 [TBL] [Abstract][Full Text] [Related]
19. Prediction of Prognosis for Prostatic Adenocarcinoma by Combined Histological Grading and Clinical Staging. Gleason DF; Mellinger GT; J Urol; 2017 Feb; 197(2S):S134-S139. PubMed ID: 28012760 [No Abstract] [Full Text] [Related]